-
公开(公告)号：US20240100105A1
公开(公告)日：2024-03-28
申请号：US18481324
申请日：2023-10-05
Applicant: BIOMX LTD. , YEDA RESEARCH AND DEVELOPMENT CO. LTD.
Inventor： Eyal Weinstock , Hava Ben-David , Kobi Konstantin Sudakov , Ayelet Moses , Sarah Rachel Pollock , Rotem Sorek , Naomi Bluma Zak
CPC classification number: A61K35/76 , A61K9/0014 , A61K45/06 , A61P17/10 , A61P31/04 , C12N2795/00032
Abstract: Bacteriophage compositions and therapeutic uses thereof. In particular, compositions of lytic bacteriophages that are capable of lysing Propionibacterium acnes (P. acnes) bacterial strains associated with acne and biofilms, thereby treating or preventing acne and biofilms.
-
公开(公告)号：US20240075139A1
公开(公告)日：2024-03-07
申请号：US17766705
申请日：2020-10-07
Applicant: Universität zu Köln , Yeda Research and Development Co., Ltd. Weizmann Institute of Science
Inventor： Florian Klein , Matthias Zehner , Stefanie Ehrhardt , Ron Diskin
CPC classification number: A61K39/42 , A61P37/04 , A61K2039/55
Abstract: The present invention relates to a method for obtaining monoclonal human antibodies directed against an infectious pathogen, monoclonal human antibodies or binding fragments thereof which are directed against an infectious pathogen as obtained by the method of the invention, a pharmaceutical composition comprising such monoclonal human antibodies, a kit comprising such antibodies, and the monoclonal antibodies or binding fragments thereof and the pharmaceutical composition and the kit for use as a medicament and in the treatment or prevention of a disease caused by the infectious pathogen.
-
823.发明公开公开(公告)号：US20240052038A1
公开(公告)日：2024-02-15
申请号：US18360222
申请日：2023-07-27
Inventor： Ester Yoles , Berit Olsen Krogh , Allan Jensen , Jan Egebjerg , Carol David , Kuti Baruch , Michal Eisenbach-Schwartz
IPC: C07K16/28
CPC classification number: C07K16/2827 , A61K2039/505
Abstract: The present specification discloses modified anti-PD-L1 antibodies that abolishes Fc-related effector function and enhances clearance rate while maintaining therapeutic efficacy for neurodegenerative disease modification. The present specification also discloses nucleic acid sequences and expression constructs encoding such modified anti-PD-L1 antibodies as well as methods of making such modified anti-PD-L1 antibodies. In addition, the present specification discloses methods of treatment and uses that employ an administration regime of the disclosed anti-PD-L1 antibodies that ensures the antibodies are present for only a specific period of time and then are sufficiently cleared from the body to ensure treatment efficacy is maintained.
-
公开(公告)号：US20240043820A1
公开(公告)日：2024-02-08
申请号：US18266385
申请日：2021-12-13
Inventor： Oliver Rackham , Aleksandra Filipovska , Pascal Vos , Sarel-Jacob Fleishman , Olga Khersonsky
CPC classification number: C12N9/22 , C12N15/63 , C12N2310/20
Abstract: Provided herein are Cas9 proteins comprising SEQ ID NO:1 or a sequence at least 80% identical thereto, wherein: the amino acid residues at positions 765 to 780 are replaced by the amino acid sequence of SEQ ID NO:5 or SEQ ID NO:6; the amino acid residues at positions 838 to 853 are replaced by the amino acid sequence of SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9 or SEQ ID NO:10; and/or the amino acid residues at positions 911 to 925 are replaced by the amino acid sequence of SEQ ID NO:11, SEQ ID NO:12 or SEQ ID NO:13. Also provided are Cas9 proteins comprising an HNH domain comprising the amino acid sequence of SEQ ID NO:14 or a sequence at least 80% identical thereto, wherein: the amino acid residues at positions 1 to 16 are replaced by the amino acid sequence of SEQ ID NO:5 or SEQ ID NO:6; the amino acid residues at positions 74 to 89 are replaced by the amino acid sequence of SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9 or SEQ ID NO:10; and/or the amino acid residues at positions 147 to 161 are replaced by the amino acid sequence of SEQ ID NO:11, SEQ ID NO:12 or SEQ ID NO:13.
-
公开(公告)号：US20240026262A1
公开(公告)日：2024-01-25
申请号：US18369233
申请日：2023-09-18
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Yaqub HANNA
Abstract: Methods and devices for ex-utero mouse embryonic development are provided. Accordingly, there is provided a method of ex-utero culturing a mouse embryo at a zygote stage under conditions that allow developments of the embryo to organogenesis or any developmental stage therein-between. Also provided a fetal incubation system, and methods of using same.
-
Patent Agency Ranking
公开(公告)号：US11873322B2
公开(公告)日：2024-01-16
申请号：US17254932
申请日：2019-06-25
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Yosef Shaul , Nina Reuven
IPC: C07K14/005 , A61K31/7088 , A61K38/46 , C12N7/00 , C12N9/22 , C12N15/11 , C12N15/90
CPC classification number: C07K14/005 , A61K31/7088 , A61K38/465 , C12N7/00 , C12N9/22 , C12N15/11 , C12N15/907 , C07K2319/00 , C12N2310/20 , C12N2710/00022 , C12N2710/00033 , C12N2800/80
Abstract: A recombinant system for improving genome editing via homologous recombination is disclosed. The system comprising a first nucleic acid sequence encoding a DNA editing agent having a double strand DNA cutting activity and a second nucleic acid sequence encoding a polypeptide capable of increasing homologous recombination in a target cell.
-
公开(公告)号：US20240009286A1
公开(公告)日：2024-01-11
申请号：US18234902
申请日：2023-08-17
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Ravid STRAUSSMAN , Oded SANDLER , Reut RIFF
IPC: A61K39/00 , A61K39/395 , A61P35/00
CPC classification number: A61K39/0011 , A61K39/3955 , A61P35/00 , A61K2039/523 , A61K2039/522
Abstract: A vaccine comprising tumor-homing bacteria which are genetically modified to express at least one cancer-associated antigen and a pharmaceutically acceptable carrier is disclosed. Uses thereof are also disclosed.
-
公开(公告)号：US20230406837A1
公开(公告)日：2023-12-21
申请号：US18334385
申请日：2023-06-14
Applicant: Yeda Research and Development Co., Ltd.
Inventor： Nir LONDON , Rambabu Reddi
IPC: C07D333/48
CPC classification number: C07D333/48
Abstract: Provided herein are Sulfamate compounds for use in modulating an activity of peptidyl-prolyl isomerase NIMA-interacting-1 (Pin1).
-
公开(公告)号：US11841410B2
公开(公告)日：2023-12-12
申请号：US17585812
申请日：2022-01-27
Inventor： Noam Ben-Eliezer , Noam Omer , Meirav Galun
CPC classification number: G01R33/50 , A61B5/055 , G01R33/5602 , G01R33/5608
Abstract: Method for mapping the transverse relaxation times (T2) in a magnetic resonance imaging (MRI) scan defined over a plurality of pixels, where each pixel is associated with a multicomponent T2 (mcT2) signal, comprises: accessing a computer readable medium storing an mcT2 dictionary having a set of synthetic mcT2 signals, and selecting a subset of synthetic mcT2 signals for which correlations between the synthetic mcT2 signals and pixels in the MRI scan are highest among the set. For each of at least a portion of the pixels, a respective mcT2 scan signal is fitted to the subset to provide, a plurality of T2 values for the pixel. A T2 map of the MRI scan is generated based on the T2 values.
-
公开(公告)号：US20230364062A1
公开(公告)日：2023-11-16
申请号：US18134064
申请日：2023-04-13
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Liran SHLUSH , Tom FLEISCHER , Benjamin GEIGER , Minhua SU
IPC: A61K31/426 , C12Q1/6827 , A61P35/02
CPC classification number: A61K31/426 , C12Q1/6827 , A61P35/02
Abstract: A method is disclosed for treating or preventing a myeloid malignancy in a subject harboring a mutation in SRSF2 comprising:
(a) analyzing in a sample of the subject for the presence of an SRSF2 mutation; and
(b) administering to the subject a therapeutically effective amount of a Rho Kinase inhibitor, or an inhibitor of a downstream effector thereof, upon identification of SRSF2 mutation.
-
-
-
-
-
-
-
-
-
Search Results
1003
records
(took 0.03 seconds)
